======= IKZF1 =======
== Gene Information ==
* **Official Symbol**: IKZF1
* **Official Name**: IKAROS family zinc finger 1
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=10320|10320]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q13422|Q13422]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=IKZF1&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20IKZF1|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/603023|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene encodes a transcription factor that belongs to the family of zinc-finger DNA-binding proteins associated with chromatin remodeling. The expression of this protein is restricted to the fetal and adult hemo-lymphopoietic system, and it functions as a regulator of lymphocyte differentiation. Several alternatively spliced transcript variants encoding different isoforms have been described for this gene. Most isoforms share a common C-terminal domain, which contains two zinc finger motifs that are required for hetero- or homo-dimerization, and for interactions with other proteins. The isoforms, however, differ in the number of N-terminal zinc finger motifs that bind DNA and in nuclear localization signal presence, resulting in members with and without DNA-binding properties. Only a few isoforms contain the requisite three or more N-terminal zinc motifs that confer high affinity binding to a specific core DNA sequence element in the promoters of target genes. The non-DNA-binding isoforms are largely found in the cytoplasm, and are thought to function as dominant-negative factors. Overexpression of some dominant-negative isoforms have been associated with B-cell malignancies, such as acute lymphoblastic leukemia (ALL). [provided by RefSeq, May 2014].
* **UniProt Summary**: Transcription regulator of hematopoietic cell differentiation (PubMed:17934067). Binds gamma-satellite DNA (PubMed:17135265, PubMed:19141594). Plays a role in the development of lymphocytes, B- and T-cells. Binds and activates the enhancer (delta-A element) of the CD3-delta gene. Repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. Regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. Targets the 2 chromatin-remodeling complexes, NuRD and BAF (SWI/SNF), in a single complex (PYR complex), to the beta- globin locus in adult erythrocytes. Increases normal apoptosis in adult erythroid cells. Confers early temporal competence to retinal progenitor cells (RPCs) (By similarity). Function is isoform-specific and is modulated by dominant-negative inactive isoforms (PubMed:17135265, PubMed:17934067). {ECO:0000250|UniProtKB:Q03267, ECO:0000269|PubMed:10204490, ECO:0000269|PubMed:17135265, ECO:0000269|PubMed:17934067, ECO:0000269|PubMed:19141594}.
|zf-C2H2|
|nuclear pericentric heterochromatin|
|erythrocyte differentiation|
|erythrocyte homeostasis|
|myeloid cell homeostasis|
|protein heterooligomerization|
|mesoderm development|
|homeostasis of number of cells|
|transcription regulatory region DNA binding|
|myeloid cell differentiation|
|lymphocyte differentiation|
|protein domain specific binding|
|leukocyte differentiation|
|lymphocyte activation|
|protein complex oligomerization|
|hemopoiesis|
|protein-containing complex|
|hematopoietic or lymphoid organ development|
|immune system development|
|DNA-binding transcription factor activity|
|chromatin organization|
|leukocyte activation|
|chromosome organization|
|cell activation|
|negative regulation of transcription, DNA-templated|
|positive regulation of transcription by RNA polymerase II|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|negative regulation of RNA metabolic process|
|cell cycle|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|DNA binding|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|positive regulation of transcription, DNA-templated|
|negative regulation of biosynthetic process|
|protein-containing complex assembly|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|homeostatic process|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|tissue development|
|protein-containing complex subunit organization|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp429|Rapamycin 0.001μM R08 exp429]]|-1.9|
|[[:results:exp67|BVD-523 15μM R02 exp67]]|-1.83|
|[[:results:exp217|Mdivi-1 15μM R05 exp217]]|-1.82|
|[[:results:exp501|Methotrexate 0.01μM R08 exp501]]|1.71|
|[[:results:exp342|Calcium Ionophore 0.4μM R07 exp342]]|1.73|
|[[:results:exp455|Benzoate 10000μM R08 exp455]]|1.74|
|[[:results:exp208|Vinblastine 0.015μM R05 exp208]]|1.77|
|[[:results:exp93|DABN racemic mixture R03 exp93]]|1.78|
|[[:results:exp450|Artemisinin 50μM R08 exp450]]|1.83|
|[[:results:exp536|Vitamin-D3 40μM R08 exp536]]|1.87|
|[[:results:exp443|SNS-032 15μM R08 exp443]]|1.95|
|[[:results:exp530|Thioridazine 5μM R08 exp530]]|1.95|
|[[:results:exp357|Dorsomorphin 5μM R07 exp357]]|2.01|
|[[:results:exp452|Azithromycin 100μM R08 exp452]]|2.02|
|[[:results:exp275|Citral 75μM R06 exp275]]|2.04|
|[[:results:exp487|Hinokiflavone 12μM R08 exp487]]|2.04|
|[[:results:exp94|Nocodazole 0.1μM R03 exp94]]|2.06|
|[[:results:exp68|Clomiphene 4.4μM R02 exp68]]|2.11|
|[[:results:exp485|GSK626616 14μM R08 exp485]]|2.12|
|[[:results:exp492|iCRT14 30μM R08 exp492]]|2.14|
|[[:results:exp456|Benzoate 20000μM R08 exp456]]|2.17|
|[[:results:exp515|PU-H71 1μM R08 exp515]]|2.34|
|[[:results:exp439|QNZ 0.01μM R08 exp439]]|2.5|
|[[:results:exp234|Ethanol 0.01 R05 exp234]]|2.54|
|[[:results:exp431|Rotenone 0.07μM R08 exp431]]|2.56|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|2.57|
|[[:results:exp466|Cannabidiol 20μM R08 exp466]]|2.62|
|[[:results:exp488|Hippuristanol 0.12μM R08 exp488]]|2.63|
|[[:results:exp474|CR131-b 0.005μM R08 exp474]]|2.78|
|[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|2.87|
|[[:results:exp259|6-Thio-2-deoxyguanosine 2μM R06 exp259]]|2.88|
|[[:results:exp445|∆-9-Tetrahydrocannabinol 30μM R08 exp445]]|3.05|
|[[:results:exp468|CB-5083 0.4μM R08 exp468]]|3.17|
|[[:results:exp489|Hippuristanol 0.12μM R08 exp489 no dilution day6]]|3.22|
|[[:results:exp301|VER-155008 3.9μM R06 exp301]]|3.26|
|[[:results:exp335|Aminopterin 0.005μM R07 exp335]]|3.48|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|3.83|
|[[:results:exp529|Thimerosal 0.85μM R08 exp529]]|4.11|
|[[:results:exp416|Tubacin 1.6μM R07 exp416]]|4.12|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|4.47|
^Gene^Correlation^
|[[:human genes:i:ikzf2|IKZF2]]|0.59|
|[[:human genes:z:zbtb7a|ZBTB7A]]|0.431|
|[[:human genes:f:flcn|FLCN]]|0.425|
|[[:human genes:c:chd7|CHD7]]|0.411|
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 10753
* **Expression level (log2 read counts)**: 7.37
{{:chemogenomics:nalm6 dist.png?nolink |}}